Medical ReviewPolicy

Pages are candidates for medical review when they discuss prescription treatments, dosing, contraindications, side effects, treatment eligibility, safety monitoring, or clinically sensitive comparisons.

This usually includes medication guides, safety pages, side effect articles, treatment program explanations, and content that could affect how a reader evaluates risks or next steps in care.

Medical review focuses on factual accuracy, completeness of safety context, appropriate clinical caveats, and whether patient-facing language could be misunderstood as personal medical advice.

Reviewers may assess statements about eligibility, adverse effects, contraindications, dose escalation, monitoring, expected results, care pathways, and language describing pharmacies or providers.

Trimi's provider is Dr. Sean Arora, MD, a licensed provider in the Arora Health 50-state telemedicine network. Arora Health providers review patient eligibility for compounded GLP-1 weight management therapy.

Arora Health serves as Trimi's clinical infrastructure partner, a 50-state medical service organization (MSO) that maintains state-by-state provider licensure and credentialing across the 50 US states. When Dr. Arora is not the assigned provider, another credentialed Arora provider handles the intake under the same clinical protocols described on this page.

Prescriptions are dispensed by Trimi's named 503A community sterile compounding pharmacy partner: BelieveRx (Texas State Board of Pharmacy license #35264). It is a state-licensed 503A community sterile compounding pharmacy that prepares each prescription for an individual patient following USP <797> sterile-compounding standards, under state board of pharmacy oversight.

Eligibility is determined individually by a licensed provider from the medical assessment, which covers medical history, current medications and weight-related conditions such as type 2 diabetes, hypertension, dyslipidemia, sleep apnea or established cardiovascular disease. Brand-label BMI thresholds are reference information and do not define Trimi's eligibility criteria.

Content review references the Endocrine Society's Clinical Practice Guideline on pharmacological management of obesity in adults, the American Association of Clinical Endocrinology (AACE) Comprehensive Type 2 Diabetes Management Algorithm, and the prescribing information for the FDA-approved brand-name products Wegovy and Ozempic (semaglutide) and Mounjaro and Zepbound (tirzepatide).

Contraindication screening includes personal or family history of medullary thyroid carcinoma (MTC), Multiple Endocrine Neoplasia type 2 (MEN 2) syndrome, history of pancreatitis, severe gastrointestinal disease, severe renal impairment, current pregnancy or breastfeeding, and prior serious hypersensitivity reaction to GLP-1 receptor agonists.

In all cases, a medically reviewed page should still be read as general education rather than personalized care instructions.

We revisit medical content when there are meaningful updates to treatment safety information, prescribing guidance, regulatory context, site offerings, or patient support workflows.

Content may also be re-reviewed when editorial teams flag clinical ambiguity or when readers report a possible issue that requires confirmation.

Medical review does not replace a direct evaluation by a licensed clinician. It does not confirm that any specific treatment is appropriate for any particular patient, and it should not be used as a substitute for urgent or emergency care.

A patient-provider relationship begins only through the appropriate clinical intake and review process, not by reading site content alone.